Related Experiment Video
Updated: Mar 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Damon A Bell1, Gerald F Watts2
1School of Medicine & Pharmacology, University of Western Australia, Perth, Western Australia, Australia; Lipid Disorders Clinic, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia; Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Western Australia, Australia.
Emerging therapies for hypertriglyceridemia offer new treatment avenues. However, caution is advised as cardiovascular outcome benefits are not consistently demonstrated despite triglyceride reduction.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Metabolic Disorders
Background:
- Hypertriglyceridemia is a multifactorial condition requiring diverse therapeutic strategies.
- Current management involves a broad range of options, with ongoing research into novel agents.
Purpose of the Study:
- To review current and emerging therapeutic options for hypertriglyceridemia.
- To emphasize novel pharmacological agents and their mechanisms of action.
Main Methods:
- Systematic literature search of PubMed and Embase.
- Inclusion of recent international meeting abstracts on triglyceride-lowering agents.
- Reference review of identified articles.
Main Results:
- Numerous therapeutic options exist for hypertriglyceridemia.
- Mechanisms of triglyceride reduction are complex and not always fully understood.
- Magnitude of triglyceride reduction and outcome study findings are detailed.
Conclusions:
- The field of hypertriglyceridemia management is advancing with new therapies nearing development.
- Cardiovascular outcome benefits of some agents require further investigation despite triglyceride-lowering effects.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Drug Therapy
Antianxiety Medications
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

